Bioengineering advances in pancreatic cancer organoids for reproducible tumor microenvironment modeling

Pancreatic ductal adenocarcinoma (PDAC) remains lethal due to late-stage diagnosis and limited non-surgical treatment options. Its intratumoral heterogeneity and desmoplastic tumor microenvironment (TME) drive invasion, immune escape, and treatment failure. Patient-derived organoids (PDOs) have emerged as efficient model platforms for simulating the TME and preserving tumor heterogeneity and enabling functional testing in vitro; however, conventional PDO cultures lack defined and controllable microenvironmental components and often exhibited limited reproducibility, physiological fidelity, and observability. This review synthesizes recent bioengineering advances that upgrade pancreatic cancer PDO platforms across three interconnected dimensions: (1) engineered extracellular matrices and biofabrication for reproducible construction; (2) co-culture, microfluidic, and bioreactor systems for physiological fidelity; (3) imaging AI and biosensor pipelines for quantitative monitoring. We highlight practical design principles and remaining bottlenecks for standardization, scalability, and clinical translation.